Evidence map›Paper›PMID 41445850›Full record

ArticleImmunotherapy advances2025

[

Sarah R Verhoeff, Evelien A J van Genugten, Iris A E van der Hoorn, Shoko Vos, Lieke L van der Woude, Francesco Ciompi, Ingrid Jolanda M de Vries, Carla M L van Herpen, Sandra Heskamp, Ad F T M Verhagen and 4 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03514719 (PD-L1 Imaging in Non Small Cell Lung Cancer'), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03514719 phase1completednot on this map

PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)

TypeinterventionalSponsorRadboud University Medical CenterRan2018 to 2021Enrolled24ConditionsNon Small Cell Lung CancerArms89Zr-avelumab PET, Avelumab
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sarah R VerhoeffDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Evelien A J van GenugtenDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
Iris A E van der HoornDepartment of Medical BioSciences, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Shoko VosDepartment of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
Lieke L van der WoudeDepartment of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
Francesco CiompiDepartment of Pathology, Computational Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
Ingrid Jolanda M de VriesDepartment of Medical BioSciences, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Carla M L van HerpenDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Sandra HeskampDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
Ad F T M VerhagenDepartment of Cardiothoracic Surgery, Radboud University Medical Center, Nijmegen, The Netherlands.
Guus R M van den HeuvelDepartment of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Berber PietDepartment of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Michel M van den HeuvelDepartment of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Erik H J G AarntzenDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0002-3809-0182

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Immune checkpoint inhibitor treatment in non-small cell lung cancer (NSCLC) expands to early stages of disease. The neoadjuvant setting allows to investigate the mechanism-of-action of immune therapy using molecular imaging and tissue analysis. We investigated the safety and feasibility of programed cell death ligand-1 (PD-L1) PET-imaging with Methods: This Phase I-II study (NCT03514719) enrolled 20 patients with Stage Ia-IIIa NSCLC who received two cycles of avelumab (10 mg/kg Q2W) prior to surgery. In the imaging optimization part, [ Results: [ Conclusion: [

Indexed as

avelumabimmune checkpoint inhibitorsimmunoPETneoadjuvantNSCLCPD-L1

Identifiers

PMID41445850
PMCPMC12724429

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.